General practitioner study: fosfomycin trometamol versus amoxycillin clavulanate in acute urinary tract infections.
A clinical trial comparing 5 days' treatment with amoxycillin/clavulanate (group A) and a single dose of fosfomycin trometamol (group B) is presented. The study was done in symptomatic patients presenting to their family practitioner, with the microbiological testing being carried out in a university hospital laboratory. Of 62 patients with significant bacteriuria, 29 were given amoxycillin/clavulanate and 33 fosfomycin trometamol, in a randomized fashion. Cure rates 1 week and 5 weeks after the end of treatment were 72 and 65% in group A and 85 and 81% in group B. Adverse events assessed in 141 patients were unusual (10.1% in group A and 8.3% in group B) and were mild in nature. The results of this study suggest that single-dose treatment with fosfomycin trometamol is effective and acceptable as a conventional course of amoxycillin clavulanate for the treatment of simple acute dysuria and/or frequency with infection.
Cooper
J
J
Earnswood Medical Centre, Crewe, London, UK.
Raeburn
A L
AL
Brumfitt
W
W
Hamilton-Miller
J M
JM
D000208:Acute Disease; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D001437:Bacteriuria / Q000188:drug therapy*; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use; D005194:Family Practice; D005260:Female; D005578:Fosfomycin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012074:Remission Induction; D013997:Time Factors; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002969:Clavulanic Acids; D005578:Fosfomycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin